Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

In May, the FDA granted 5 significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Research conducted at Uskudar University (Istanbul, Turkey) explored the neuroprotective potential of ethanolic extracts of ...

Adding niraparib to abiraterone acetate and prednisone may help slow cancer growth for patients with metastatic ...

An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase ...

CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

Live Updates Live Coverage Has Ended Nvidia Drives Stock Market Higher 4:25 pm Strong performance from Dow Jones Industrial ...

The FTSE 100 index closed up 12.76 points, 0.2%, at 8,787.02. The FTSE 250 ended down 11.19 points, 0.1%, at 21,017.78, and the AIM All-Share closed up 5.38 points, 0.7%, at 753.51.